Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Published on 05 Jun 2025

Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo

in Pharmacology of Anti-Cancer Drugs

Essha Chatterjee
Ram Sharma
Biswajit Dey
Hoshiyar Singh
Aliva Naik
Anjesh Khan
Santanu Basak
Ankush Bansode
Ritika Sachdeva
Anamika Sharma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1544666

1,340 views

Mini Review

Published on 05 Jun 2025

Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications

in Pharmacology of Anti-Cancer Drugs

Chengwei Li
Xiaoyan Qi
Min Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572195

1,105 views

Original Research

Published on 04 Jun 2025

SPAG6 Promotes Multiple Myeloma Through Activation of the MAPK/ERK Signaling Pathway

in Pharmacology of Anti-Cancer Drugs

Junnan Li
Xinyu Yan
Li Ding
Jiaxiu Yin
Ping Li
Lin Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572621

740 views

Review

Published on 04 Jun 2025

Role and therapeutic potential of the NEDD4 family in breast cancer

in Pharmacology of Anti-Cancer Drugs

Xiaoxiao Zhang
Sijie Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1587675

877 views

Original Research

Published on 04 Jun 2025

Pomolic acid induces ferroptosis-mediated cell death in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Wenbin Ji
Yanbin Zhang
Wenhao Ji
Hui Zhang
Biao Qin
Xiao-Liang Xing
Zaiqi Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1567942

1,153 views

Original Research

Published on 02 Jun 2025

SNORA13 antisense oligonucleotides enhances the therapeutical effects of 5-fluorouracil in colon adenocarcinoma

in Pharmacology of Anti-Cancer Drugs

Yanzhi Wang
Huihui An
Yaou Zhang
Qing Rex Lyu
Zhe Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564682

1,451 views

Original Research

Published on 30 May 2025

Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches

in Pharmacology of Anti-Cancer Drugs

Yanrong Guo
Songyan Han
Qinxiang Guo
Jinfang Zhai
Xiaohui Ren
Shengshu Li
Jianchun Duan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1591643

835 views

Systematic Review

Published on 30 May 2025

Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Yijun Wang
Yicong Wang
Lei Wang
He Yuan
Yongai Yu
Daju Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566604

807 views

Original Research

Published on 30 May 2025

HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment

in Pharmacology of Anti-Cancer Drugs

Shihao Liang
Xiaoya Shao
Xueqiong Meng
Ying Cui
Chuanyue Sun
Jie Sun
Binghui Zhang
Guomin Shen
Ling Qin
Haiping Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1612916

700 views

Original Research

Published on 30 May 2025

Hypoxia-induced tRF-3Thr-CGT promotes hepatocellular carcinoma progression via mitochondrial energy metabolism remodeling dependent on the mtDNA-translation mechanism

in Pharmacology of Anti-Cancer Drugs

Xianzhi Qu
Buhan Liu
Duo Jin
Yue Ma
Mingjun Liu
Xiaoyu Yan
Jing Su
Lei Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1549373

755 views

Original Research

Published on 29 May 2025

A multimodal approach for establishing ACTL6A and ERCC1 as chemoresistance genes in locally advanced head and neck cancer

in Pharmacology of Anti-Cancer Drugs

Raushan Kumar Chaudhary
Prakash Patil
Vijith Vittal Shetty
Uday Venkat Mateti
Praveenkumar Shetty

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1541987

903 views

Original Research

Published on 29 May 2025

Polypharmacy, drug–drug interactions and adverse drug reactions in older Chinese cancer patients: evidence from CHARLS

in Pharmacology of Anti-Cancer Drugs

Zijun Yan
Ke-qin Fan
Ting Yu
Ning Su
Yan Zou
Liangjing Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1579023

1,430 views

Original Research

Accepted on 27 May 2025

Targeted Degradation of EGFR 19Del by Protac Suppresses Tumor Growth in Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Lianhua Piao
Ying Gao
Yangyang Su
Qihui Li
Xiaofeng Yuan
Wangqiu He
Wanzhou Zhao
Janne Kulpakko
Pei-Chieng Cha
Shan Chang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1604661

309 views

Original Research

Published on 27 May 2025

Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Jie Cui
Pengyong Xu
Changying Guo
Yong Guan
Kejia Zhu
Sentai Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1618898

817 views

Review

Published on 27 May 2025

Unravelling the link between circadian clock genes and brain tumors: From pathological disruptions to potential therapeutic interventions

in Pharmacology of Anti-Cancer Drugs

Amirah Albaqami

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1617713

1,236 views

Original Research

Published on 27 May 2025

Anticancer effects of zinc ion-mediated DNA demethylation in oesophageal squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Bin Zhou
Changchun Wang
Yueyu Huang
Xuping Yang
Ting Ye
Lize Shen
Qiaoli Lv
Weimin Mao
An Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1559675

800 views